Business
Medical Marijuana, Inc. Portfolio Company AXIM® Biotechnologies Receives New U.S. Patent Issuance for Topical Cream Containing Cannabinoids
Medical Marijuana, Inc. Portfolio Company AXIM® Biotechnologies Receives New U.S. Patent Issuance for Topical Cream Containing Cannabinoids.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\n\n\n\nMedical Marijuana, Inc. Portfolio Company AXIM® Biotechnologies Receives New U.S. Patent Issuance for Topical Cream Containing Cannabinoids\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMedical Marijuana, Inc. Portfolio Company AXIM® Biotechnologies Receives New U.S. Patent Issuance for Topical Cream Containing Cannabinoids\nPR Newswire\nSAN DIEGO, March 27, 2019\n\n\n\nSAN DIEGO, March 27, 2019 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced that its portfolio company AXIM® Biotechnologies (\"AXIM® Biotech\" or \"AXIM\") (OTCQB: AXIM), a world leader in cannabinoid research and development, has received the issuance of a Notice of Allowance for a patent from the United States Patent and Trademark Office (USPTO) on a method to treat atopic dermatitis, also known as eczema, using a topical cream containing cannabinoids - specifically cannabidiol (\"CBD\") and cannabigerol (\"CBG\"). The USPTO granted this allowance from AXIM's patent application 16/106,524 filed on August 21, 2018. \n\"As a large investor in AXIM, we are proud to see the company expand their intellectual property protection as they develop this innovative topical cream that aims to treat atopic dermatitis among other skin conditions,\" said Dr. Stuart Titus, CEO of Medical Marijuana, Inc. \"We look forward to continuing our relationship with AXIM as they research the potential therapeutic benefits of cannabinoids and launch additional products that look to transform both the cannabinoid-based pharmaceutical and nutraceutical markets.\"\nAXIM's topical cream is projected to be one of the first CBG products available on the market and will be formulated with cannabinoids and utilize the company's proprietary combination of CBG and CBD. With this patent allowance, AXIM has formulated a topical cream for relief of itching, pain and inflammation that often accompany atopic dermatitis. \n\"Research has shown evidence that both CBD and CBG provide anti-inflammatory and pain relief benefits,\" s...